Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)
Study Details
Study Description
Brief Summary
This phase II LUNG-MAP treatment trial studies how well selpercatinib works in treating patients with RET fusion-positive non-small cell lung cancer that is stage IV or has come back (recurrent). Selpercatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Detailed Description
PRIMARY OBJECTIVE:
- To evaluate the objective response rate (ORR) (confirmed complete or partial response) by blinded independent centralized review (BICR) associated with selpercatinib (LOXO-292) in patients with previously-treated stage IV or recurrent RET fusion-positive non-small cell lung cancer (NSCLC).
SECONDARY OBJECTIVES:
-
To evaluate the duration of BICR-assessed response among BICR responders. II. To evaluate the frequency and severity of toxicities. III. To evaluate the investigator-assessed objective response rate (confirmed complete or partial response).
-
To evaluate duration of investigator-assessed response among patients with a response as determined by the local investigator.
-
To evaluate investigator-assessed progression-free survival (IA-PFS). VI. To evaluate BICR-assessed PFS. VII. To evaluate overall survival (OS).
VIII. Among patients with brain metastases at baseline:
VIIIa. To evaluate the central nervous system (CNS) response rate (confirmed complete response [CR]).
VIIIb. To evaluate the duration of intracranial response among patients with a CNS response.
TRANSLATIONAL MEDICINE OBJECTIVES:
-
To collect, process, and bank cell-free deoxyribonucleic acid (cfDNA) at baseline, progression, and end of treatment for future development of a proposal to evaluate comprehensive next-generation sequencing of circulating tumor deoxyribonucleic acid (ctDNA).
-
To establish a tissue/blood repository from patients with refractory non-small cell lung cancer (NSCLC).
OUTLINE:
Patients receive selpercatinib orally (PO) twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 6 months for 2 years and then at the end of 3 years from date of sub-study registration.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Treatment (selpercatinib) Patients receive selpercatinib orally PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
Drug: Selpercatinib
Given PO
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Response rate by blinded independent centralized review (BICR) [Up to 3 years from date of sub-study registration]
A response will be confirmed by a complete response (CR) or partial response (PR). Proportions and associated confidence intervals will be calculated.
Secondary Outcome Measures
- Incidence of adverse events [Up to 3 years from date of sub-study registration]
Will be assessed using Common Terminology Criteria for Adverse Event version 5.0.
- BICR-progression-free survival (PFS) [From date of sub-study registration to date of first documentation of progression assessed by BICR or symptomatic deterioration, or death due to any cause, assessed up to 3 years from date of sub-study registration]
Will be estimated using the method of Kaplan-Meier. The Brookmeyer-Crowley method will be used to estimate confidence intervals for the median using Greenwood's formula and based on a log-log transformation applied on the survival function for landmark times
- Investigator-assessed (IA) PFS [From date of sub-study registration to date of first documentation of progression assessed by local review or symptomatic deterioration, or death due to any cause, assessed up to 3 years from date of sub-study registration]
Will be estimated using the method of Kaplan-Meier. The Brookmeyer-Crowley method will be used to estimate confidence intervals for the median using Greenwood's formula and based on a log-log transformation applied on the survival function for landmark times
- Overall survival [Up to 3 years from date of sub-study registration]
Will be estimated using the method of Kaplan-Meier. The Brookmeyer-Crowley method will be used to estimate confidence intervals for the median using Greenwood's formula and based on a log-log transformation applied on the survival function for landmark times
- BICR-duration of response (DOR) [From date of first documentation of confirmed response (CR or PR) to date of first documentation of progression assessed by BICR or symptomatic deterioration, or death due to any cause among patients who achieve, assessed at 6 and 12 months]
Will be evaluated among patients who achieve a confirmed response. Will be estimated using the method of Kaplan-Meier. The Brookmeyer-Crowley method will be used to estimate confidence intervals for the median using Greenwood's formula and based on a log-log transformation applied on the survival function for landmark times. The median DOR and percentage with DOR at landmark times at 6 and 12 months after documentation of confirmed response will be estimated.
- Central nervous system (CNS) response rate [Baseline]
Will be assessed among patients with brain metastases. Will be estimated using the method of Kaplan-Meier. The Brookmeyer-Crowley method will be used to estimate confidence intervals for the median using Greenwood's formula and based on a log-log transformation applied on the survival function for landmark times
- Duration of intracranial response among patients with a CNS response [Baseline]
Will be assessed among patients with brain metastases. Will be estimated using the method of Kaplan-Meier. The Brookmeyer-Crowley method will be used to estimate confidence intervals for the median using Greenwood's formula and based on a log-log transformation applied on the survival function for landmark times
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients must have been assigned to S1900B based on biomarker analysis of tissue and/or blood and determined to have RET fusion-positive NSCLC as defined here:
-
Patients must have RET fusion-positive NSCLC as determined by the Foundation Medicine (FMI) tissue-assay, other tumor-based assays such as next-generation sequencing (NGS), polymerase chain reaction (PCR), or follicular in situ hybridization (FISH), or by cfDNA blood assay. Patients with RET fusions detected by immunohistochemistry (IHC) alone are not eligible. The testing must be done within a laboratory with Clinical Laboratory Improvement Act (CLIA), International Organization for Standardization (ISO/International Electrotechnical Commission (IEC), College of American Pathologists (CAP), or similar certification. Presence of RET fusions detected on tests performed outside of LUNGMAP must have been confirmed by the study biomarker review panel
-
For patients whose prior therapy was for stage IV or recurrent disease, the patient must have received at least one line of a platinum-based chemotherapy regimen. For patients whose prior systemic therapy was for stage I-III disease only (i.e. patient has not received any treatment for stage IV or recurrent disease), disease progression on platinum-based chemotherapy must have occurred within one year from the last date that the patient received that therapy. Prior anti-PD-1/PD-L1 therapy, alone or in combination (e.g. nivolumab, pembrolizumab, or durvalumab) is allowed
-
Patients must be negative for all additional validated oncogenic drivers that could cause resistance to LOXO-292 treatment. This includes EGFR sensitizing mutations, EGFR T790M, ALK gene fusion, ROS1 gene fusion, KRAS activating mutation, BRAF V600E mutation and MET exon 14 skipping mutation or high-level amplification and expression
-
Note: EGFR, ALK, ROS, KRAS, and BRAF testing is performed as part of the LUNGMAP screening/pre-screening FoundationOne test. If prior data is not available, results from the FMI testing must be obtained prior to sub-study registration
-
Patients must have measurable disease documented by computed tomography (CT) or magnetic resonance imaging (MRI). The CT from a combined positron emission tomography (PET)/CT may be used to document only non-measurable disease unless it is of diagnostic quality. Measurable disease must be assessed within 28 days prior to sub-study registration. Pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease. Non-measurable disease must be assessed within 42 days prior to sub-study registration. All disease must be assessed and documented on the Baseline Tumor Assessment Form. Patients whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease (in the opinion of the treating investigator) prior to registration. CT and MRI scans must be submitted for central review via transfer of images and data (TRIAD)
-
Patients must have a CT or MRI scan of the brain to evaluate for CNS disease within 42 days prior to sub-study registration
-
Patients with evidence of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load on suppressive therapy within 28 days prior to registration
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. Patients with HCV infection who are currently on treatment must have an undetectable HCV viral load within 28 days prior to registration
-
Patients with known human immunodeficiency virus (HIV) infection are eligible, provided they are on effective anti-retroviral therapy and have undetectable viral load at their most recent viral load test and within 6 months prior to registration
-
Patients must be able to swallow capsules
-
Patients must have progressed (in the opinion of the treating physician) following the most recent line of therapy
-
Patients must have recovered (=< grade 1) from any side effects of prior therapy. Patients must not have received any radiation therapy within 14 days prior to sub-study registration
-
Absolute neutrophil count (ANC) >= 1,500/mcl (obtained within 28 days prior to sub-study registration)
-
Platelet count >= 100,000 mcl (obtained within 28 days prior to sub-study registration)
-
Serum bilirubin =< institutional upper limit of normal (IULN) (within 28 days prior to sub-study registration). For patients with liver metastases, bilirubin must be =< 5 x IULN
-
Either alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 2 x IULN (within 28 days prior to sub-study registration) (if both ALT and AST are done, both must be =< 2 IULN). For patients with liver metastases, bilirubin and either ALT or AST must be =< 5 x IULN (if both ALT and AST are done, both must be =< 5 x IULN)
-
Serum creatinine =< the IULN or calculated creatinine clearance >= 50 mL/min using the following Cockcroft-Gault formula (within 28 days prior to sub-study registration)
-
Patients must have Zubrod performance status 0-1 documented within 28 days prior to sub-study registration
-
Pre-study history and physical exam must be obtained within 28 days prior to sub-study registration
-
No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years
-
Patients must have electrolytes and blood urea nitrogen (BUN) performed within 14 days prior to sub-study registration
-
Patients must agree to have blood specimens submitted for circulating tumor DNA (ctDNA)
-
Patients must also be offered participation in banking and in the correlative studies for collection and future use of specimens
-
Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
-
As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
-
Patients with impaired decision-making capacity are eligible as long as their neurological or psychological condition does not preclude their safe participation in the study (e.g., tracking pill consumption and reporting adverse events to the investigator)
Exclusion Criteria:
-
Patients must not have received any prior treatment with selective anti-RET inhibitors (anti-RET multikinase inhibitors are permitted)
-
Patient must not have leptomeningeal disease, spinal cord compression or brain metastases unless: (1) metastases have been locally treated and have remained clinically controlled and asymptomatic for at least 14 days following treatment, and prior to registration, AND (2) patient has no residual neurological dysfunction and has been off corticosteroids for at least 24 hours prior to sub-study registration
-
Patients must not have received any prior systemic therapy (systemic chemotherapy, immunotherapy or investigational drug) within 14 days prior to sub-study registration
-
Patients must not be planning to receive any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment while receiving treatment on this study. Concurrent use of hormones for non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptable
-
Patient must not have had a major surgery within 14 days prior to sub-study registration. Patient must have fully recovered from the effects of prior surgery in the opinion of the treating investigator
-
Patients must not have any grade III/IV cardiac disease as defined by the New York Heart Association Criteria (i.e., patients with cardiac disease resulting in marked limitation of physical activity or resulting in inability to carry on any physical activity without discomfort), unstable angina pectoris, and myocardial infarction within 6 months, or serious uncontrolled cardiac arrhythmia
-
Patients must not have a QT interval by Fridericia (QTcF) > 470 msec based on the electrocardiogram (ECG) within 28 days prior to registration. It is suggested that a local cardiologist review the QTcF intervals
-
Patients must not have any clinically significant uncontrolled systemic illness, including but not limited to uncontrolled infection, requiring intravenous antibiotics, unstable angina pectoris, myocardial infarction within the past 6 months, uncontrolled cardiac arrhythmias, uncontrolled hypertension, or uncontrolled diabetes mellitus
-
Uncontrolled diabetes: Patients who have a diagnosis of diabetes must have an hemoglobin (Hb) A1C < 7% within 28 days prior to registration. The same criterion will be used in patients with confirmed diagnosis of diabetes mellitus who have been on a stable dietary or therapeutic regimen for this condition in the last three months
-
Uncontrolled blood pressure and hypertension: All blood pressure measurements within the 28 days prior to registration must be systolic blood pressure (SBP) =< 180 and diastolic blood pressure (DBP) =< 100. An exception can be made by a healthcare provider for a patient with a single blood pressure elevation who upon rechecking has a blood pressure within the parameters above
-
Patients must not have any impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of LOXO-292 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection, or active peptic ulcer disease)
-
Patients must not be planning to receive any strong inhibitors or inducers of CYP3A4 at least 14 days prior to sub-study registration and throughout protocol treatment
-
Patients must not be planning to use proton pump inhibitors (PPIs) at least one week prior to sub-study registration and throughout protocol treatment
-
Patients must not be pregnant or nursing. Women study patients of reproductive potential and fertile men study patients and their partners must abstain or use effective contraception (including barrier method) while receiving study treatment and for at least 3 months after the last dose of LOXO-292. Male study patients must agree not to donate sperm for 6 months after the last dose of LOXO-292. A woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation. However, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Fairbanks Memorial Hospital | Fairbanks | Alaska | United States | 99701 |
| 2 | University of Arkansas for Medical Sciences | Little Rock | Arkansas | United States | 72205 |
| 3 | Kaiser Permanente-Anaheim | Anaheim | California | United States | 92806 |
| 4 | Sutter Auburn Faith Hospital | Auburn | California | United States | 95602 |
| 5 | Kaiser Permanente-Baldwin Park | Baldwin Park | California | United States | 91706 |
| 6 | Kaiser Permanente-Bellflower | Bellflower | California | United States | 90706 |
| 7 | Alta Bates Summit Medical Center-Herrick Campus | Berkeley | California | United States | 94704 |
| 8 | Kaiser Permanente-Fontana | Fontana | California | United States | 92335 |
| 9 | Palo Alto Medical Foundation-Fremont | Fremont | California | United States | 94538 |
| 10 | Kaiser Permanente - Harbor City | Harbor City | California | United States | 90710 |
| 11 | Kaiser Permanente-Irvine | Irvine | California | United States | 92618 |
| 12 | Loma Linda University Medical Center | Loma Linda | California | United States | 92354 |
| 13 | Kaiser Permanente Los Angeles Medical Center | Los Angeles | California | United States | 90027 |
| 14 | Kaiser Permanente-Cadillac | Los Angeles | California | United States | 90034 |
| 15 | Palo Alto Medical Foundation-Camino Division | Mountain View | California | United States | 94040 |
| 16 | Kaiser Permanente-Ontario | Ontario | California | United States | 91761 |
| 17 | Palo Alto Medical Foundation Health Care | Palo Alto | California | United States | 94301 |
| 18 | Stanford Cancer Institute Palo Alto | Palo Alto | California | United States | 94304 |
| 19 | Kaiser Permanente - Panorama City | Panorama City | California | United States | 91402 |
| 20 | Kaiser Permanente-Riverside | Riverside | California | United States | 92505 |
| 21 | Sutter Roseville Medical Center | Roseville | California | United States | 95661 |
| 22 | Sutter Medical Center Sacramento | Sacramento | California | United States | 95816 |
| 23 | University of California Davis Comprehensive Cancer Center | Sacramento | California | United States | 95817 |
| 24 | Kaiser Permanente-San Diego Zion | San Diego | California | United States | 92120 |
| 25 | California Pacific Medical Center-Pacific Campus | San Francisco | California | United States | 94115 |
| 26 | Kaiser Permanente-San Marcos | San Marcos | California | United States | 92078 |
| 27 | Palo Alto Medical Foundation-Santa Cruz | Santa Cruz | California | United States | 95065 |
| 28 | Palo Alto Medical Foundation-Sunnyvale | Sunnyvale | California | United States | 94086 |
| 29 | Sutter Solano Medical Center/Cancer Center | Vallejo | California | United States | 94589 |
| 30 | Presbyterian Intercommunity Hospital | Whittier | California | United States | 90602 |
| 31 | Kaiser Permanente-Woodland Hills | Woodland Hills | California | United States | 91367 |
| 32 | University of Colorado Hospital | Aurora | Colorado | United States | 80045 |
| 33 | Rocky Mountain Cancer Centers-Boulder | Boulder | Colorado | United States | 80304 |
| 34 | UCHealth Memorial Hospital Central | Colorado Springs | Colorado | United States | 80909 |
| 35 | Memorial Hospital North | Colorado Springs | Colorado | United States | 80920 |
| 36 | Rocky Mountain Cancer Centers-Midtown | Denver | Colorado | United States | 80218 |
| 37 | Poudre Valley Hospital | Fort Collins | Colorado | United States | 80524 |
| 38 | Cancer Care and Hematology-Fort Collins | Fort Collins | Colorado | United States | 80528 |
| 39 | North Colorado Medical Center | Greeley | Colorado | United States | 80631 |
| 40 | UCHealth Greeley Hospital | Greeley | Colorado | United States | 80631 |
| 41 | UCHealth Highlands Ranch Hospital | Highlands Ranch | Colorado | United States | 80129 |
| 42 | Rocky Mountain Cancer Centers-Littleton | Littleton | Colorado | United States | 80120 |
| 43 | Rocky Mountain Cancer Centers-Sky Ridge | Lone Tree | Colorado | United States | 80124 |
| 44 | UCHealth Lone Tree Health Center | Lone Tree | Colorado | United States | 80124 |
| 45 | Medical Center of the Rockies | Loveland | Colorado | United States | 80538 |
| 46 | McKee Medical Center | Loveland | Colorado | United States | 80539 |
| 47 | Hartford Hospital | Hartford | Connecticut | United States | 06102 |
| 48 | Veterans Affairs Connecticut Healthcare System-West Haven Campus | West Haven | Connecticut | United States | 06516 |
| 49 | Bayhealth Hospital Kent Campus | Dover | Delaware | United States | 19901 |
| 50 | Bayhealth Hospital Sussex Campus | Milford | Delaware | United States | 19963 |
| 51 | Mount Sinai Comprehensive Cancer Center at Aventura | Aventura | Florida | United States | 33180 |
| 52 | Mount Sinai Medical Center | Miami Beach | Florida | United States | 33140 |
| 53 | Moffitt Cancer Center | Tampa | Florida | United States | 33612 |
| 54 | Northside Hospital | Atlanta | Georgia | United States | 30342 |
| 55 | Northeast Georgia Medical Center Braselton | Braselton | Georgia | United States | 30517 |
| 56 | Atlanta VA Medical Center | Decatur | Georgia | United States | 30033 |
| 57 | Northside Hospital - Duluth | Duluth | Georgia | United States | 30096 |
| 58 | Northeast Georgia Medical Center-Gainesville | Gainesville | Georgia | United States | 30501 |
| 59 | Northside Hospital - Gwinnett | Lawrenceville | Georgia | United States | 30046 |
| 60 | Lewis Cancer and Research Pavilion at Saint Joseph's/Candler | Savannah | Georgia | United States | 31405 |
| 61 | Suburban Hematology Oncology Associates - Snellville | Snellville | Georgia | United States | 30078 |
| 62 | Hawaii Cancer Care - Savio | 'Aiea | Hawaii | United States | 96701 |
| 63 | Pali Momi Medical Center | 'Aiea | Hawaii | United States | 96701 |
| 64 | Hawaii Cancer Care Inc-POB II | Honolulu | Hawaii | United States | 96813 |
| 65 | Queen's Cancer Cenrer - POB I | Honolulu | Hawaii | United States | 96813 |
| 66 | Queen's Medical Center | Honolulu | Hawaii | United States | 96813 |
| 67 | Straub Clinic and Hospital | Honolulu | Hawaii | United States | 96813 |
| 68 | Queen's Cancer Center - Kuakini | Honolulu | Hawaii | United States | 96817 |
| 69 | Saint Luke's Mountain States Tumor Institute | Boise | Idaho | United States | 83712 |
| 70 | Saint Luke's Cancer Institute - Fruitland | Fruitland | Idaho | United States | 83619 |
| 71 | Saint Luke's Cancer Institute - Meridian | Meridian | Idaho | United States | 83642 |
| 72 | Saint Luke's Cancer Institute - Nampa | Nampa | Idaho | United States | 83686 |
| 73 | Saint Luke's Cancer Institute - Twin Falls | Twin Falls | Idaho | United States | 83301 |
| 74 | Illinois CancerCare-Bloomington | Bloomington | Illinois | United States | 61704 |
| 75 | Illinois CancerCare-Canton | Canton | Illinois | United States | 61520 |
| 76 | Illinois CancerCare-Carthage | Carthage | Illinois | United States | 62321 |
| 77 | Northwestern University | Chicago | Illinois | United States | 60611 |
| 78 | Cancer Care Specialists of Illinois - Decatur | Decatur | Illinois | United States | 62526 |
| 79 | Illinois CancerCare-Dixon | Dixon | Illinois | United States | 61021 |
| 80 | Crossroads Cancer Center | Effingham | Illinois | United States | 62401 |
| 81 | Illinois CancerCare-Eureka | Eureka | Illinois | United States | 61530 |
| 82 | NorthShore University HealthSystem-Evanston Hospital | Evanston | Illinois | United States | 60201 |
| 83 | Illinois CancerCare-Galesburg | Galesburg | Illinois | United States | 61401 |
| 84 | NorthShore University HealthSystem-Glenbrook Hospital | Glenview | Illinois | United States | 60026 |
| 85 | NorthShore University HealthSystem-Highland Park Hospital | Highland Park | Illinois | United States | 60035 |
| 86 | Illinois CancerCare-Kewanee Clinic | Kewanee | Illinois | United States | 61443 |
| 87 | Illinois CancerCare-Macomb | Macomb | Illinois | United States | 61455 |
| 88 | Loyola University Medical Center | Maywood | Illinois | United States | 60153 |
| 89 | Cancer Care Center of O'Fallon | O'Fallon | Illinois | United States | 62269 |
| 90 | Illinois CancerCare-Ottawa Clinic | Ottawa | Illinois | United States | 61350 |
| 91 | Illinois CancerCare-Pekin | Pekin | Illinois | United States | 61554 |
| 92 | Illinois CancerCare-Peoria | Peoria | Illinois | United States | 61615 |
| 93 | Illinois CancerCare-Peru | Peru | Illinois | United States | 61354 |
| 94 | Illinois CancerCare-Princeton | Princeton | Illinois | United States | 61356 |
| 95 | Genesis Cancer Center - Silvis | Silvis | Illinois | United States | 61282 |
| 96 | Parkview Regional Medical Center | Fort Wayne | Indiana | United States | 46845 |
| 97 | Goshen Center for Cancer Care | Goshen | Indiana | United States | 46526 |
| 98 | Franciscan Health Indianapolis | Indianapolis | Indiana | United States | 46237 |
| 99 | Franciscan Health Mooresville | Mooresville | Indiana | United States | 46158 |
| 100 | Memorial Hospital of South Bend | South Bend | Indiana | United States | 46601 |
| 101 | Mary Greeley Medical Center | Ames | Iowa | United States | 50010 |
| 102 | McFarland Clinic PC - Ames | Ames | Iowa | United States | 50010 |
| 103 | McFarland Clinic PC-Boone | Boone | Iowa | United States | 50036 |
| 104 | Medical Oncology and Hematology Associates-West Des Moines | Clive | Iowa | United States | 50325 |
| 105 | Mercy Cancer Center-West Lakes | Clive | Iowa | United States | 50325 |
| 106 | Greater Regional Medical Center | Creston | Iowa | United States | 50801 |
| 107 | Genesis Medical Center - East Campus | Davenport | Iowa | United States | 52803 |
| 108 | Genesis Cancer Care Institute | Davenport | Iowa | United States | 52804 |
| 109 | Iowa Cancer Specialists | Davenport | Iowa | United States | 52807 |
| 110 | Medical Oncology and Hematology Associates-Laurel | Des Moines | Iowa | United States | 50314 |
| 111 | Mercy Medical Center - Des Moines | Des Moines | Iowa | United States | 50314 |
| 112 | McFarland Clinic PC-Trinity Cancer Center | Fort Dodge | Iowa | United States | 50501 |
| 113 | McFarland Clinic PC-Jefferson | Jefferson | Iowa | United States | 50129 |
| 114 | McFarland Clinic PC-Marshalltown | Marshalltown | Iowa | United States | 50158 |
| 115 | Mercy Medical Center-West Lakes | West Des Moines | Iowa | United States | 50266 |
| 116 | HaysMed University of Kansas Health System | Hays | Kansas | United States | 67601 |
| 117 | University of Kansas Cancer Center | Kansas City | Kansas | United States | 66160 |
| 118 | Olathe Health Cancer Center | Olathe | Kansas | United States | 66061 |
| 119 | University of Kansas Cancer Center-Overland Park | Overland Park | Kansas | United States | 66210 |
| 120 | Salina Regional Health Center | Salina | Kansas | United States | 67401 |
| 121 | University of Kansas Health System Saint Francis Campus | Topeka | Kansas | United States | 66606 |
| 122 | University of Kansas Hospital-Westwood Cancer Center | Westwood | Kansas | United States | 66205 |
| 123 | University of Kentucky/Markey Cancer Center | Lexington | Kentucky | United States | 40536 |
| 124 | Medical Center of Baton Rouge | Baton Rouge | Louisiana | United States | 70816 |
| 125 | Ochsner High Grove | Baton Rouge | Louisiana | United States | 70836 |
| 126 | Ochsner Medical Center Kenner | Kenner | Louisiana | United States | 70065 |
| 127 | Ochsner Medical Center Jefferson | New Orleans | Louisiana | United States | 70121 |
| 128 | Harold Alfond Center for Cancer Care | Augusta | Maine | United States | 04330 |
| 129 | Waldo County General Hospital | Belfast | Maine | United States | 04915 |
| 130 | MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford | Biddeford | Maine | United States | 04005 |
| 131 | Penobscot Bay Medical Center | Rockport | Maine | United States | 04856 |
| 132 | MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford | Sanford | Maine | United States | 04073 |
| 133 | Maine Medical Partners - South Portland | South Portland | Maine | United States | 04106 |
| 134 | Western Maryland Regional Medical Center | Cumberland | Maryland | United States | 21502 |
| 135 | UMass Memorial Medical Center - University Campus | Worcester | Massachusetts | United States | 01655 |
| 136 | Saint Joseph Mercy Hospital | Ann Arbor | Michigan | United States | 48106 |
| 137 | Bronson Battle Creek | Battle Creek | Michigan | United States | 49017 |
| 138 | IHA Hematology Oncology Consultants-Brighton | Brighton | Michigan | United States | 48114 |
| 139 | Saint Joseph Mercy Brighton | Brighton | Michigan | United States | 48114 |
| 140 | IHA Hematology Oncology Consultants-Canton | Canton | Michigan | United States | 48188 |
| 141 | Saint Joseph Mercy Canton | Canton | Michigan | United States | 48188 |
| 142 | IHA Hematology Oncology Consultants-Chelsea | Chelsea | Michigan | United States | 48118 |
| 143 | Saint Joseph Mercy Chelsea | Chelsea | Michigan | United States | 48118 |
| 144 | Henry Ford Macomb Hospital-Clinton Township | Clinton Township | Michigan | United States | 48038 |
| 145 | Henry Ford Hospital | Detroit | Michigan | United States | 48202 |
| 146 | Genesee Cancer and Blood Disease Treatment Center | Flint | Michigan | United States | 48503 |
| 147 | Genesee Hematology Oncology PC | Flint | Michigan | United States | 48503 |
| 148 | Genesys Hurley Cancer Institute | Flint | Michigan | United States | 48503 |
| 149 | Spectrum Health at Butterworth Campus | Grand Rapids | Michigan | United States | 49503 |
| 150 | Allegiance Health | Jackson | Michigan | United States | 49201 |
| 151 | West Michigan Cancer Center | Kalamazoo | Michigan | United States | 49007 |
| 152 | Sparrow Hospital | Lansing | Michigan | United States | 48912 |
| 153 | Hope Cancer Clinic | Livonia | Michigan | United States | 48154 |
| 154 | Saint Mary Mercy Hospital | Livonia | Michigan | United States | 48154 |
| 155 | Spectrum Health Reed City Hospital | Reed City | Michigan | United States | 49677 |
| 156 | Ascension Saint Mary's Hospital | Saginaw | Michigan | United States | 48601 |
| 157 | Oncology Hematology Associates of Saginaw Valley PC | Saginaw | Michigan | United States | 48604 |
| 158 | Marie Yeager Cancer Center | Saint Joseph | Michigan | United States | 49085 |
| 159 | Ascension Saint Joseph Hospital | Tawas City | Michigan | United States | 48764 |
| 160 | Munson Medical Center | Traverse City | Michigan | United States | 49684 |
| 161 | Metro Health Hospital | Wyoming | Michigan | United States | 49519 |
| 162 | IHA Hematology Oncology Consultants-Ann Arbor | Ypsilanti | Michigan | United States | 48197 |
| 163 | Sanford Joe Lueken Cancer Center | Bemidji | Minnesota | United States | 56601 |
| 164 | Essentia Health - Deer River Clinic | Deer River | Minnesota | United States | 56636 |
| 165 | Essentia Health Cancer Center | Duluth | Minnesota | United States | 55805 |
| 166 | Essentia Health Hibbing Clinic | Hibbing | Minnesota | United States | 55746 |
| 167 | Minneapolis VA Medical Center | Minneapolis | Minnesota | United States | 55417 |
| 168 | United Hospital | Saint Paul | Minnesota | United States | 55102 |
| 169 | Essentia Health Sandstone | Sandstone | Minnesota | United States | 55072 |
| 170 | Essentia Health Virginia Clinic | Virginia | Minnesota | United States | 55792 |
| 171 | University of Mississippi Medical Center | Jackson | Mississippi | United States | 39216 |
| 172 | Saint Francis Medical Center | Cape Girardeau | Missouri | United States | 63703 |
| 173 | Siteman Cancer Center at West County Hospital | Creve Coeur | Missouri | United States | 63141 |
| 174 | Parkland Health Center - Farmington | Farmington | Missouri | United States | 63640 |
| 175 | Truman Medical Centers | Kansas City | Missouri | United States | 64108 |
| 176 | University of Kansas Cancer Center - North | Kansas City | Missouri | United States | 64154 |
| 177 | University of Kansas Cancer Center - Lee's Summit | Lee's Summit | Missouri | United States | 64064 |
| 178 | University of Kansas Cancer Center at North Kansas City Hospital | North Kansas City | Missouri | United States | 64116 |
| 179 | Washington University School of Medicine | Saint Louis | Missouri | United States | 63110 |
| 180 | Mercy Hospital South | Saint Louis | Missouri | United States | 63128 |
| 181 | Siteman Cancer Center-South County | Saint Louis | Missouri | United States | 63129 |
| 182 | Missouri Baptist Medical Center | Saint Louis | Missouri | United States | 63131 |
| 183 | Mercy Hospital Saint Louis | Saint Louis | Missouri | United States | 63141 |
| 184 | Siteman Cancer Center at Saint Peters Hospital | Saint Peters | Missouri | United States | 63376 |
| 185 | Sainte Genevieve County Memorial Hospital | Sainte Genevieve | Missouri | United States | 63670 |
| 186 | Mercy Hospital Springfield | Springfield | Missouri | United States | 65804 |
| 187 | Missouri Baptist Sullivan Hospital | Sullivan | Missouri | United States | 63080 |
| 188 | Missouri Baptist Outpatient Center-Sunset Hills | Sunset Hills | Missouri | United States | 63127 |
| 189 | Community Hospital of Anaconda | Anaconda | Montana | United States | 59711 |
| 190 | Bozeman Deaconess Hospital | Bozeman | Montana | United States | 59715 |
| 191 | Benefis Healthcare- Sletten Cancer Institute | Great Falls | Montana | United States | 59405 |
| 192 | OptumCare Cancer Care at Oakey | Las Vegas | Nevada | United States | 89102 |
| 193 | OptumCare Cancer Care at Fort Apache | Las Vegas | Nevada | United States | 89148 |
| 194 | Renown Regional Medical Center | Reno | Nevada | United States | 89502 |
| 195 | New Hampshire Oncology Hematology PA-Concord | Concord | New Hampshire | United States | 03301 |
| 196 | Solinsky Center for Cancer Care | Manchester | New Hampshire | United States | 03103 |
| 197 | Virtua Samson Cancer Center | Moorestown | New Jersey | United States | 08057 |
| 198 | Virtua Voorhees | Voorhees | New Jersey | United States | 08043 |
| 199 | University of New Mexico Cancer Center | Albuquerque | New Mexico | United States | 87102 |
| 200 | New Mexico Oncology Hematology Consultants | Albuquerque | New Mexico | United States | 87109 |
| 201 | Presbyterian Kaseman Hospital | Albuquerque | New Mexico | United States | 87110 |
| 202 | Presbyterian Rust Medical Center/Jorgensen Cancer Center | Rio Rancho | New Mexico | United States | 87124 |
| 203 | James J Peters VA Medical Center | Bronx | New York | United States | 10468 |
| 204 | Mary Imogene Bassett Hospital | Cooperstown | New York | United States | 13326 |
| 205 | Arnot Ogden Medical Center/Falck Cancer Center | Elmira | New York | United States | 14905 |
| 206 | University of Rochester | Rochester | New York | United States | 14642 |
| 207 | Randolph Hospital | Asheboro | North Carolina | United States | 27203 |
| 208 | Cone Health Cancer Center at Alamance Regional | Burlington | North Carolina | United States | 27215 |
| 209 | Rex Hematology Oncology Associates-Cary | Cary | North Carolina | United States | 27518 |
| 210 | Durham VA Medical Center | Durham | North Carolina | United States | 27705 |
| 211 | Rex Hematology Oncology Associates-Garner | Garner | North Carolina | United States | 27529 |
| 212 | Cone Health Cancer Center | Greensboro | North Carolina | United States | 27403 |
| 213 | Margaret R Pardee Memorial Hospital | Hendersonville | North Carolina | United States | 28791 |
| 214 | Rex Cancer Center | Raleigh | North Carolina | United States | 27607 |
| 215 | Rex Hematology Oncology Associates-Blue Ridge | Raleigh | North Carolina | United States | 27607 |
| 216 | Rex Cancer Center of Wakefield | Raleigh | North Carolina | United States | 27614 |
| 217 | Sanford Bismarck Medical Center | Bismarck | North Dakota | United States | 58501 |
| 218 | Sanford Broadway Medical Center | Fargo | North Dakota | United States | 58122 |
| 219 | Sanford Roger Maris Cancer Center | Fargo | North Dakota | United States | 58122 |
| 220 | UHHS-Chagrin Highlands Medical Center | Beachwood | Ohio | United States | 44122 |
| 221 | Strecker Cancer Center-Belpre | Belpre | Ohio | United States | 45714 |
| 222 | Geauga Hospital | Chardon | Ohio | United States | 44024 |
| 223 | Adena Regional Medical Center | Chillicothe | Ohio | United States | 45601 |
| 224 | Case Western Reserve University | Cleveland | Ohio | United States | 44106 |
| 225 | Columbus Oncology and Hematology Associates Inc | Columbus | Ohio | United States | 43214 |
| 226 | Grant Medical Center | Columbus | Ohio | United States | 43215 |
| 227 | The Mark H Zangmeister Center | Columbus | Ohio | United States | 43219 |
| 228 | Doctors Hospital | Columbus | Ohio | United States | 43228 |
| 229 | Delaware Health Center-Grady Cancer Center | Delaware | Ohio | United States | 43015 |
| 230 | Marietta Memorial Hospital | Marietta | Ohio | United States | 45750 |
| 231 | OhioHealth Marion General Hospital | Marion | Ohio | United States | 43302 |
| 232 | UH Seidman Cancer Center at Landerbrook Health Center | Mayfield Heights | Ohio | United States | 44124 |
| 233 | UH Seidman Cancer Center at Lake Health Mentor Campus | Mentor | Ohio | United States | 44060 |
| 234 | UH Seidman Cancer Center at Southwest General Hospital | Middleburg Heights | Ohio | United States | 44130 |
| 235 | Licking Memorial Hospital | Newark | Ohio | United States | 43055 |
| 236 | University Hospitals Parma Medical Center | Parma | Ohio | United States | 44129 |
| 237 | Southern Ohio Medical Center | Portsmouth | Ohio | United States | 45662 |
| 238 | University Hospitals Portage Medical Center | Ravenna | Ohio | United States | 44266 |
| 239 | UH Seidman Cancer Center at Firelands Regional Medical Center | Sandusky | Ohio | United States | 44870 |
| 240 | ProMedica Flower Hospital | Sylvania | Ohio | United States | 43560 |
| 241 | University Hospitals Sharon Health Center | Wadsworth | Ohio | United States | 44281 |
| 242 | UH Seidman Cancer Center at Saint John Medical Center | Westlake | Ohio | United States | 44145 |
| 243 | UHHS-Westlake Medical Center | Westlake | Ohio | United States | 44145 |
| 244 | Genesis Healthcare System Cancer Care Center | Zanesville | Ohio | United States | 43701 |
| 245 | University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | United States | 73104 |
| 246 | Mercy Hospital Oklahoma City | Oklahoma City | Oklahoma | United States | 73120 |
| 247 | Kaiser Permanente Northwest | Portland | Oregon | United States | 97227 |
| 248 | Oregon Health and Science University | Portland | Oregon | United States | 97239 |
| 249 | Salem Hospital | Salem | Oregon | United States | 97301 |
| 250 | Fox Chase Cancer Center - East Norriton Hospital Outpatient Center | East Norriton | Pennsylvania | United States | 19401 |
| 251 | Ephrata Cancer Center | Ephrata | Pennsylvania | United States | 17522 |
| 252 | Adams Cancer Center | Gettysburg | Pennsylvania | United States | 17325 |
| 253 | Cherry Tree Cancer Center | Hanover | Pennsylvania | United States | 17331 |
| 254 | UPMC Pinnacle Cancer Center/Community Osteopathic Campus | Harrisburg | Pennsylvania | United States | 17109 |
| 255 | Sechler Family Cancer Center | Lebanon | Pennsylvania | United States | 17042 |
| 256 | Thomas Jefferson University Hospital | Philadelphia | Pennsylvania | United States | 19107 |
| 257 | Fox Chase Cancer Center | Philadelphia | Pennsylvania | United States | 19111 |
| 258 | Temple University Hospital | Philadelphia | Pennsylvania | United States | 19140 |
| 259 | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh | Pennsylvania | United States | 15232 |
| 260 | Pottstown Hospital | Pottstown | Pennsylvania | United States | 19464 |
| 261 | UPMC Susquehanna | Williamsport | Pennsylvania | United States | 17701 |
| 262 | WellSpan Health-York Cancer Center | York | Pennsylvania | United States | 17403 |
| 263 | Medical University of South Carolina | Charleston | South Carolina | United States | 29425 |
| 264 | Prisma Health Cancer Institute - Easley | Easley | South Carolina | United States | 29640 |
| 265 | Prisma Health Cancer Institute - Butternut | Greenville | South Carolina | United States | 29605 |
| 266 | Prisma Health Cancer Institute - Faris | Greenville | South Carolina | United States | 29605 |
| 267 | Prisma Health Cancer Institute - Eastside | Greenville | South Carolina | United States | 29615 |
| 268 | Prisma Health Cancer Institute - Greer | Greer | South Carolina | United States | 29650 |
| 269 | Prisma Health Cancer Institute - Seneca | Seneca | South Carolina | United States | 29672 |
| 270 | Prisma Health Cancer Institute - Spartanburg | Spartanburg | South Carolina | United States | 29307 |
| 271 | Sanford Cancer Center Oncology Clinic | Sioux Falls | South Dakota | United States | 57104 |
| 272 | Sanford USD Medical Center - Sioux Falls | Sioux Falls | South Dakota | United States | 57117-5134 |
| 273 | The Don and Sybil Harrington Cancer Center | Amarillo | Texas | United States | 79106 |
| 274 | Parkland Memorial Hospital | Dallas | Texas | United States | 75235 |
| 275 | UT Southwestern/Simmons Cancer Center-Dallas | Dallas | Texas | United States | 75390 |
| 276 | Bon Secours Memorial Regional Medical Center | Mechanicsville | Virginia | United States | 23116 |
| 277 | Bon Secours Saint Francis Medical Center | Midlothian | Virginia | United States | 23114 |
| 278 | Bon Secours Saint Mary's Hospital | Richmond | Virginia | United States | 23226 |
| 279 | Jefferson Healthcare | Port Townsend | Washington | United States | 98368 |
| 280 | Edwards Comprehensive Cancer Center | Huntington | West Virginia | United States | 25701 |
| 281 | Langlade Hospital and Cancer Center | Antigo | Wisconsin | United States | 54409 |
| 282 | Duluth Clinic Ashland | Ashland | Wisconsin | United States | 54806 |
| 283 | Aurora Cancer Care-Southern Lakes VLCC | Burlington | Wisconsin | United States | 53105 |
| 284 | Aurora Health Care Germantown Health Center | Germantown | Wisconsin | United States | 53022 |
| 285 | Aurora Cancer Care-Grafton | Grafton | Wisconsin | United States | 53024 |
| 286 | Aurora BayCare Medical Center | Green Bay | Wisconsin | United States | 54311 |
| 287 | Aurora Cancer Care-Kenosha South | Kenosha | Wisconsin | United States | 53142 |
| 288 | Gundersen Lutheran Medical Center | La Crosse | Wisconsin | United States | 54601 |
| 289 | Aurora Bay Area Medical Group-Marinette | Marinette | Wisconsin | United States | 54143 |
| 290 | Aspirus Medford Hospital | Medford | Wisconsin | United States | 54451 |
| 291 | Froedtert Menomonee Falls Hospital | Menomonee Falls | Wisconsin | United States | 53051 |
| 292 | Aurora Cancer Care-Milwaukee | Milwaukee | Wisconsin | United States | 53209 |
| 293 | Aurora Saint Luke's Medical Center | Milwaukee | Wisconsin | United States | 53215 |
| 294 | Medical College of Wisconsin | Milwaukee | Wisconsin | United States | 53226 |
| 295 | Aurora Sinai Medical Center | Milwaukee | Wisconsin | United States | 53233 |
| 296 | Vince Lombardi Cancer Clinic - Oshkosh | Oshkosh | Wisconsin | United States | 54904 |
| 297 | Aurora Cancer Care-Racine | Racine | Wisconsin | United States | 53406 |
| 298 | Vince Lombardi Cancer Clinic-Sheboygan | Sheboygan | Wisconsin | United States | 53081 |
| 299 | Aurora Medical Center in Summit | Summit | Wisconsin | United States | 53066 |
| 300 | Vince Lombardi Cancer Clinic-Two Rivers | Two Rivers | Wisconsin | United States | 54241 |
| 301 | Aspirus Regional Cancer Center | Wausau | Wisconsin | United States | 54401 |
| 302 | Aurora Cancer Care-Milwaukee West | Wauwatosa | Wisconsin | United States | 53226 |
| 303 | Aurora West Allis Medical Center | West Allis | Wisconsin | United States | 53227 |
| 304 | Froedtert West Bend Hospital/Kraemer Cancer Center | West Bend | Wisconsin | United States | 53095 |
| 305 | Marshfield Clinic - Weston Center | Weston | Wisconsin | United States | 54476 |
| 306 | Aspirus UW Cancer Center | Wisconsin Rapids | Wisconsin | United States | 54494 |
Sponsors and Collaborators
- Southwest Oncology Group
- National Cancer Institute (NCI)
Investigators
- Principal Investigator: Yasir Y Elamin, Southwest Oncology Group
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- S1900B
- NCI-2019-08097
- S1900B
- S1900B
- U10CA180888